A compound of structural formula (I): or a pharmaceutically acceptable salt thereof, wherein: T is CR 3 ; U is CR 1 ; V is CR 2 ; W is CR 4 ; X is O; Y is: wherein Y is unsubstituted or substituted with 1, 2, or 3 substituents selected from R b ; Z is NR 5 ; each R 1 is independently selected from: -aryl-C 2-10 cycloheteroalkyl, and; -aryl-aryl, wherein each cycloheteroalkyl and aryl is unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from R a ; R 2 is selected from halogen; R 3 is hydrogen or halogen; R 4 is hydrogen; R5 is hydrogen; each R a is independently selected from the group consisting of: F, -OH, -C(CH 3 ) 2 OH, - C(CH 3 )(CH 2 OH) 2 , CN, -SO 2 CH 3 , -CH 2 SO 2 CH 3 , -SO 2 -piperidine, -C(O)NHCH 3 , - (CH 2 ) 3 CO 2 H, morpholine, pyrrolidine, pyridine, pyrimidine, oxadiazole, oxazole, tetrazole, pyrazole, thiazole, triazole, and pyridazine, wherein each CH 2 is unsubstituted or substituted with 1 or 2 substituents selected from: -(CH 2 ) 1-3 OH and -C 1-6 alkyl and wherein alkyl, cycloheteroalkyl, and heteroaryl is unsubstituted or substituted with 1, 2, 3, or 4 substituents selected from: oxo, -OH, -NH 2 , -C 1-6 alkyl, -C 1-6 alkyl substituted with 1-5 OH, and -C 3-7 cycloalkyl; each R b is independently selected from--OH and -CH 2 OH. T is CR 3 ; U is CR 1 ; V is CR 2 ; W is CR 4 ; X is O; Y is: wherein Y is unsubstituted or substituted with 1, 2, or 3 substituents selected from R b ; Z is NR 5 ; each R 1 is independently selected from: -aryl-C 2-10 cycloheteroalkyl, and; -aryl-aryl, wherein each cycloheteroalkyl and aryl is unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from R a ; R 2 is selected from halogen; R 3 is hydrogen or halogen; R 4 is hydrogen; R5 is hydrogen; each R a is independently selected from the group consisting of: F, -OH, -C(CH 3 ) 2 OH, - C(CH 3 )(CH 2 OH) 2 , CN, -SO 2 CH 3 , -CH 2 SO 2 CH 3 , -SO 2 -piperidine, -C(O)NHCH 3 , - (CH 2 ) 3 CO 2 H, morpholine, pyrrolidine, pyridine, pyrimidine, oxadiazole, oxazole, tetrazole, pyrazole, thiazole, triazole, and pyridazine, wherein each CH 2 is unsubstituted or substituted with 1 or 2 substituents selected from: -(CH 2 ) 1-3 OH and -C 1-6 alkyl and wherein alkyl, cycloheteroalkyl, and heteroaryl is unsubstituted or substituted with 1, 2, 3, or 4 substituents selected from: oxo, -OH, -NH 2 , -C 1-6 alkyl, -C 1-6 alkyl substituted with 1-5 OH, and -C 3-7 cycloalkyl; each R b is independently selected from--OH and -CH 2 OH. wherein Y is unsubstituted or substituted with 1, 2, or 3 substituents selected from R b ; Z is NR 5 ; each R 1 is independently selected from: -aryl-C 2-10 cycloheteroalkyl, and; -aryl-aryl, wherein each cycloheteroalkyl and aryl is unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from R a ; -aryl-C 2-10 cycloheteroalkyl, and; -aryl-aryl, R 2 is selected from halogen; R 3 is hydrogen or halogen; R 4 is hydrogen; R5 is hydrogen; each R a is independently selected from the group consisting of: F, -OH, -C(CH 3 ) 2 OH, - C(CH 3 )(CH 2 OH) 2 , CN, -SO 2 CH 3 , -CH 2 SO 2 CH 3 , -SO 2 -piperidine, -C(O)NHCH 3 , - (CH 2 ) 3 CO 2 H, morpholine, pyrrolidine, pyridine, pyrimidine, oxadiazole, oxazole, tetrazole, pyrazole, thiazole, triazole, and pyridazine, wherein each CH 2 is unsubstituted or substituted with 1 or 2 substituents selected from: -(CH 2 ) 1-3 OH and -C 1-6 alkyl and wherein alkyl, cycloheteroalkyl, and heteroaryl is unsubstituted or substituted with 1, 2, 3, or 4 substituents selected from: oxo, -OH, -NH 2 , -C 1-6 alkyl, -C 1-6 alkyl substituted with 1-5 OH, and -C 3-7 cycloalkyl; each R b is independently selected from--OH and -CH 2 OH. <EOS>